PHILADELPHIA – More than a quarter of brain cancer patients participating in a phase I gene therapy trial survived at least three years after treatment, prompting Tocagen Inc. to move directly into a seamless, pivotal trial following the FDA's granting of a breakthrough therapy designation earlier this year.